Genentech will use Adaptive's ClonoSeq assay for MRD testing in a CLL study. Adaptive will receive upfront and sample testing payments of undisclosed amounts.
Invitae estimated that in 2020 it would accession more than 725,000 samples and bring in more than $330 million in revenue, slightly above current Wall Street projections.
Total revenues of $36.6 million include product and service revenues, which are expected to be about $33.6 million and would be a 42 percent increase year over year.
The company also said that preliminary full-year 2019 revenues are expected to be up 6 percent, with sample-to-answer revenues up more than 20 percent.
The multistate rural health system will adopt Color technology to move to NGS and enhance online engagement for its Imagenetics clinical genomics program.
News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.
